Shanghai Medicilon Inc. (SHANGHAI MEDICILON INC) aksje

Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development; custom and zoom in synthesis; structural, in vitro, and computational biology; protein expression and purification; protein crystallization; and recombinant kinase preparation services, as well as protein target validation, compound activity screening and optimization, raw material and preparation process research, and quality standards and stability research services. The company also provides process route screening, API production process optimization, drug process research and application, pharmacology services, drug safety evaluation, biological analysis, IND filing, and TCM preclinical trial service solutions, such as pharmaceutical research, pharmacodynamics, pharmacokinetics, and toxicology. In addition, it offers lipid synthesis, liposome preparation, prescription screening, process optimization and development, quality research, safety evaluation, bioanalysis, registration and declaration, etc.; pre-formulation research, drug analysis, drug stability research, and formulation development; and cytokine and biomarker testing, bioanalysis, and flow cytometry service, as well as engages in the research and development of new drugs. Further, the company is involved in the molecular drug development business. The company was founded in 2004 and is based in Shanghai, China.